This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Mifepristone

Authoring team

This is a semisynthetic steroid which is used in combination with the prostaglandin gemeprost as an abortifacient.

Mifepristone is a 19-norsteroid, similar in structure to the progestogen norethisterone, but with a substitution of a dimethylaminophenyl group in the 11 beta position. It has a high affinity for the progesterone receptor and thus inhibits the action of endogenous progesterone, which is essential for the maintenance of pregnancy.

If given alone, mifepristone induces abortion in 60-80% of women, depending on the duration of the pregnancy. If used in combination with prostaglandins, then complete abortion occurs in about 95% of women.

Emergency contraception:

  • a systematic review concenring emergency contraception concluded that mifepristone middle dose (25-50 mg) was superior to other hormonal regimens (1)

Study evidence shows (2):

  • although rare, short-term adverse events are more likely after mifepristone-misoprostol induced abortion (IA) than procedural IA, especially for less serious adverse outcomes

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.